

#### **Cover Sheet for Information Only**

Return of Cover Page NOT required with completed form

Please fax or email a copy of this form to the Coordinating Centre within 24 hours of awareness of the event at the address below:-

Dr Natalia Igosheva RESCUE-ASDH Trial Coordinator Addenbrooke's Hospital Cambridge CB2 0QQ Tel: (+44) (0)1223 254919

Fax: (+44) (0)1223 256763 Email: Natalia.igosheva@addenbrookes.nhs.uk Sponsor address
Cambridge Clinical Trials Unit
Email: CCTU@addenbrookes.nhs.uk
Fax: 01223 256623

Chief Investigator please fax or email a copy of this form to the Clinical Trials Unit within 24 hours of receipt from site.

Trial Title: RESCUE-ASDH:Randomised Evaluation of Surgery with Craniectomy for patients Undergoing Evacuation of Acute

**Subdural Haematoma** 

**Chief Investigator: Professor Peter Hutchinson** 

Trial Co-ordinator: Dr Natalia Igosheva

Investigator sites: please complete all WHITE sections Chief Investigator: please complete all GREY sections

#### **Definitions**

**AE:** Adverse Event. Any untoward medical occurrence that happens to a patient or research participant administered a treatment which may or may not necessarily have causal relationship with this treatment.

AR: Adverse reaction. Any untoward and unintended reaction that is considered to be related to the treatment.

The Sponsor expects that all AEs and ARs are recorded on all trials from the point of Informed Consent regardless of whether a patient has yet received the treatment.

All AEs and ARs, including expected systemic and procedure-related events, should be assessed by the Investigator and recorded in detail in medical notes and Case Report Forms (CRFs)

**SAE: Serious Adverse Event.** Any AE or effect that: Results in death; Is life threatening; Requires hospitalisation or prolongation of existing hospitalisation; Results in persistent or significant disability/incapacity; Is a congenital anomaly/birth defect; Is an otherwise medically important event.

**SAR: Serious Adverse Reaction.** An SAE that is considered to be possibly, probably or definitely related to the IMP.

**SUSAR:** Suspected Unexpected Serious Adverse Reaction. An adverse reaction, which is both serious and unexpected, i.e. the nature or severity of which is not consistent with the applicable treatment and which fulfils one or more of the criteria listed above for SAE.

In this trial only Serious adverse events/reactions and surgical complications that are **Unexpected** must be reported as SAEs/SARs

**Initial Reporting:** For all initial reporting of unexpected SAE/SARs this form must be **completed fully or with as much information as possible** and sent to the RESCUE-ASDH Coordinator within **24 hours** of the incident occurring or being reported to the participating team.

**Follow-up Information:** For subsequent follow-up reporting of an unexpected SAE/SAR, **a new SAE/SAR Reporting form should be completed by the Investigator or a delegated person with just the administration details and all new or missing information only and forwarded to the RESCUE-ASDH Coordinator as soon as possible. All SAE/Rs must be followed up until resolution.** 



Trial details		Participant detail	Participant details					
Study Title: RESCUE-ASD	H ISRCTN No: ISRCTN87	370545 Initials:	Subject ID No:					
Sponsor R&D No: A093232		Date of Birth:	Gender: Male					
SAE Ref No:		d	d m m m y y y y Female					
Specifics								
	te of site awareness:	Name of person repor	-					
Initial Report	d m m m y y Has the Princ	prior to the completion of this form?	res No Centre:					
Serious Adverse Event								
Serious Adverse Event Term:								
Date of Onset:	n m y y 3 =	- 3- 3	= Worsening					
Severity	Event Summary:							
Mild Moderate Severe	Signs and Symptoms:	Signs and Symptoms:	Admission date:/					
			Discharge date d d m m m y y					
Why was the event serious?	(Provide a clear, chronological, clinical signs/examination findings).	al course of events from presentation to	o current time—including symptoms and signs at presentation/vital					
Life-threatening								
Required inpatient or prolong existing hospitalisation	jed							
Resulted in persistent or								
significant disability/incapacit  Resulted in congenital anoma								
birth defect								
Other Important Medical Ever (Please specify)	ıt							
			Please continue on another sheet if necessary					



Trial details					Participant of	letails			
Study Title:	RESCUE-ASDH	ISRCTN No:	ISRCTN	87370545	Initials:		Subject	: ID No:	
Sponsor R&D No:	A093232				Date of Birth:				
SAE Ref No:						d d m m	m y y y		
Research Proce	dures								
Protocol Treatme cedure	nt(s)/Research Pro-	Date of procedure		Date of last to out prior to S	reatment carried AE	SAE relation to the Research Procedure/ Causality Use codes	If SAE is Expected/ Unexpected Use codes	Name of Person making decision	
		d d m m m	/		m m y y				
			/	d d m	m m y y				
		d d m m m	/	d d m	m m y y				
		d d m m m	/ y y	d d m	m m y y				
					Codes:	Causality:  1 = Definitely  2 = Probably  3 = Possibly  4 = Unlikely  5 = Not related  6 = Unknown/ Not assessable	Expectedness: 1 = Expected 2 = Unexpected		



Trial details							Participant details				
Study Title: Sponsor R&D No: SAE Ref No:	RESCUE-ASDH ISRCTN No: ISRCTN87370545  A093232			Initials:  Date of Birth:  d d m m m y y y y y							
Treatment give	n to manag	e SAE									
Treatment (surgic tion) given to mar applicable)		Dose	Units i.e.: mg	Freq. i.e.: O/D	Route of Admin. Use codes	Date of treatments		End date (if applicable)  d d m m m y  d d m m m y	Route of Admin:  1 = Oral  2 = IV  3 = Sub. Cut.  4 = Topical  5 = Suppository  6 = Other (please specify)		
Any other conc	urrent cond	litions?	)								
Yes No	(If yes, pl	ease spec	cify belo	w and co	ontinue on a se	parate sheet if nec	essary)				



Trial details				Participant details				
l F	RESCUE-ASDH A093232	ISRCTN87370545	Initials:  Date of Birth:					
SAE Ref No:					d d m r	m m y y y	У	
Additional pages attached to this form:	I confirm this is a	n SAE				at this is an UNEX O RELATED SAE	Yes If no, please attach discussion with site No & send the outcome in as Follow Up form	
	PI Signature:				CI Signature			
	PI Name Printed:  Date:				CI Name Pri			
Co-ordinating of	ffice use only:					Co-ordinator		
Date event received Co-ordinating office			ate sae reported to Main EC:	d d m		Signature:		
Co-ordinating Site Trial SAE Ref. No:		R	eported to other PIs?	Yes	No	Name Printed: Date:		